Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Subcomponent Vaccine Base… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Subcomponent Vaccine Based on CTA1-DD Adjuvant with Incorporated UreB Class II Peptides Stimulates Protective Helicobacter pylori Immunity

Artikel i vetenskaplig tidskrift
Författare J. G. Nedrud
N. Bagheri
Karin Schön
W. Xin
Hilda Bergroth
Dubravka Grdic Eliasson
Nils Y Lycke
Publicerad i Plos One
Volym 8
Nummer/häfte 12
Sidor e83321
ISSN 1932-6203
Publiceringsår 2013
Publicerad vid Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi
Sidor e83321
Språk en
Länkar dx.doi.org/10.1371/journal.pone.008...
Ämnesord HEAT-LABILE ENTEROTOXIN, UREASE-B-SUBUNIT, CHOLERA-TOXIN, MUCOSAL, IMMUNIZATION, ORAL IMMUNIZATION, INDUCED REDUCTION, BALB/C MICE, MOUSE, MODEL, INFECTION, IDENTIFICATION
Ämneskategorier Mikrobiologi, Immunbiologi

Sammanfattning

A mucosal vaccine against Helicobacter pylori infection could help prevent gastric cancers and peptic ulcers. While previous attempts to develop such a vaccine have largely failed because of the requirement for safe and effective adjuvants or large amounts of well defined antigens, we have taken a unique approach to combining our strong mucosal CTA1-DD adjuvant with selected peptides from urease B (UreB). The protective efficacy of the selected peptides together with cholera toxin (CT) was first confirmed. However, CT is a strong adjuvant that unfortunately is precluded from clinical use because of its toxicity. To circumvent this problem we have developed a derivative of CT, the CTA1-DD adjuvant, that has been found safe in non-human primates and equally effective compared to CT when used intranasally. We genetically fused the selected peptides into the CTA1-DD plasmid and found after intranasal immunizations of Balb/c mice using purified CTA1-DD with 3 copies of an H. pylori urease T cell epitope (CTA1-UreB3T-DD) that significant protection was stimulated against a live challenge infection. Protection was, however, weaker than with the gold standard, bacterial lysate+CT, but considering that we only used a single epitope in nanomolar amounts the results convey optimism. Protection was associated with enhanced Th1 and Th17 immunity, but immunizations in IL-17A-deficient mice revealed that IL-17 may not be essential for protection. Taken together, we have provided evidence for the rational design of an effective mucosal subcomponent vaccine against H. pylori infection based on well selected protective epitopes from relevant antigens incorporated into the CTA1-DD adjuvant platform.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?